Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally[1] Since the start of the donation program in … Read the full press release
Better visual outcomes for patients with the AcrySof IQ PanOptix intraocular lens at near and intermediate distance vision[1] Detailed findings presented at World Ophthalmology Congress 2018 Recent survey reveals 82% of people 60+ are willing to have advanced surgical options … Read the full press release
Brentford, UK, 05-Jun-2018 — /EuropaWire/ — GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has completed the buyout of Novartis’ 36.5% stake in its Consumer Healthcare Joint Venture for $13 billion (£9.3 billion*). The transaction, which was previously announced on 27 … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, United Kingdom
Tagged buyout, Consumer HealthCare, GlaxoSmithKline plc, Healthcare, Novartis, shareholders
European Commission’s (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable earlier patient access to important medicines and positively impact healthcare systems Zessly is the third EC … Read the full press release
Posted in European Union, Germany, Healthcare, Pharma & Biotech
Tagged Europe, European Commission, infliximab, Novartis, Richard Francis, Sandoz, Zessly®
Holzkirchen, Germany, 04-May-2018 — /EuropaWire/ — Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing Application (BLA) for its proposed biosimilar rituximab. Sandoz stands behind … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Biologics Licensing Application, Biosimilar, medicine, Novartis, rituximab, Sandoz, US FDA
Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only CAR-T therapy FDA-approved for two distinct indications – in non-Hodgkin … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged CAR-T, FDA, Kymriah, leukemia, Liz Barrett, lymphoma, Novartis, oncology, Stephen J. Schuster MD, tisagenlecleucel
Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis’ leadership in biomedical research and clinical development with Pear’s expertise in digital therapeutics Novartis continues to embrace emerging … Read the full press release
Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of 85%[1] Promacta is the only TPO receptor agonist indicated for the treatment of patients … Read the full press release
MONALEESA-7 met primary endpoint of progression-free survival, demonstrating superior efficacy of Kisqali combination therapy vs. endocrine treatment alone in first-line treatment of premenopausal women with HR+/HER2- advanced breast cancer[1] Kisqali is the first CDK4/6 inhibitor to be studied in a Phase … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged breast cancer, MONALEESA-7, MONALEESA-7 trial, Novartis, premenopausal women
Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study[1] PsA can lead to reduced mobility and irreversible joint damage[2] FUTURE 5 is the largest randomized controlled … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Cosentyx, FUTURE 5, FUTURE 5 study on psoriatic arthritis, Novartis, PSA
Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in addition to standard of care including lipid-lowering therapy Effect driven … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged ACZ885, MACE, major adverse cardiovascular events, Novartis, placebo
Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is the first Phase III clinical trial to support a … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged ACZ885, CANTOS, lung cancer, Novartis
New leader to drive the digital transformation Novartis has embarked upon BASEL, 28-Aug-2017 — /EuropaWire/ — Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury’s Argos, has been appointed to the new role of Chief Digital Officer, … Read the full press release
Posted in Pharma & Biotech, Switzerland
Tagged Bertrand Bodson, Joseph Jimenez, Novartis
Total investment of EUR 105 million in Prevalje site reinforces commitment to largest Sandoz business, Anti-Infectives, and single largest global product, broad-spectrum antibiotic amoxicillin-clavulanic acid. The investment will bring 150 new jobs, more than doubling the number of employees at … Read the full press release
Posted in Investment, Pharma & Biotech, Slovenia
Tagged investment, LEK, Miro Cerar PhD, Novartis, Sandoz, Vojmir Urlep
Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevated levels of lipoprotein Lp(a) or ApoCIII, which is a potent regulator of triglycerides … Read the full press release
Rwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since September 2015, Novartis Access has delivered more than 100,000 monthly treatments to Kenya, Ethiopia and Lebanon* First-year learnings underline broader … Read the full press release
Posted in Government, Healthcare, Pharma & Biotech, Switzerland
Tagged Dr. Jonathan Kiliko, Joseph Jimenez, Novartis, Novartis Access, Rwanda
Alcon to host first live training program on the use of the CyPass® Micro-Stent, a minimally invasive glaucoma surgical device to treat cataract patients with mild to moderate primary open-angle glaucoma Two-year safety and efficacy data from landmark COMPASS study … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland, Technology
Tagged AAO annual meeting, Alcon, CyPass® Micro-Stent, Eye care leader, Franck Leveiller, glaucoma, Novartis, Sergio Duplan
Ultibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study Analyses show that Ultibro Breezhaler lowered patients’ need for rescue medication and had improved benefit-risk profile compared to Seretide, with … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged COPD, Novartis, Novartis' Ultibro® Breezhaler®, Seretide, Vasant Narasimhan
Outlines actions underway to accelerate launch of Entresto®, including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx® Highlights leading pipeline of second generation immuno-oncology assets Confirms Sandoz on track for 10 biosimilar filings by … Read the full press release
Posted in Healthcare, Management, Pharma & Biotech, Switzerland
Tagged biosimilars, eye care, Joseph Jimenez, Novartis, oncology
EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies Two formulations approved: once-daily tablet and oral suspension formulation designed for younger children who may … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?